@article{541776011a6946439d0a0f2617d80e21,
title = "B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines",
abstract = "In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.",
author = "Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Chang, {Julie E.} and Beth Christian and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Bartlett, {Nancy L.} and Budde, {L. Elizabeth} and Caimi, {Paolo F.} and {de Vos}, Sven and Bhagirathbhai Dholaria and Bita Fakhri and Fayad, {Luis E.} and Glenn, {Martha J.} and Habermann, {Thomas M.} and Francisco Hernandez-Ilizaliturri and Eric Hsi and Boyu Hu and Kaminski, {Mark S.} and Kelsey, {Christopher R.} and Nadia Khan and Susan Krivacic and LaCasce, {Ann S.} and Megan Lim and Mayur Narkhede and Rachel Rabinovitch and Praveen Ramakrishnan and Erin Reid and Roberts, {Kenneth B.} and Hayder Saeed and Smith, {Stephen D.} and Jakub Svoboda and Swinnen, {Lode J.} and Joseph Tuscano and Vose, {Julie M.} and Dwyer, {Mary A.} and Hema Sundar",
note = "Funding Information: This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. This activity is supported by an independent educational grant from AbbVie. Publisher Copyright: {\textcopyright} 2021 Harborside Press. All rights reserved.",
year = "2021",
month = nov,
doi = "10.6004/jnccn.2021.0054",
language = "English (US)",
volume = "19",
pages = "1218--1230",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "11",
}